Search

We present white light images of the Sun's corona acquired during the total Solar Eclipses on August 21, 2017 in mountains north of Boise Idaho USA and on July 2, 2019 south of Copiapo Chile. In both cases the viewing was excellent, altitudes ∼ 1200 m and relative humidity ∼ 10. We used an Orion equatorial reflecting telescope with 203 mm diameter aperture and 1000 mm focal length for f4.9 optics. A computer-controlled Canon EOS Rebel T3i digital camera was used. We plan to use our 2019 eclipse images for analysis since the Sun is near solar minimum so 2D steady state MHD equations can be used. We present a plan to process the images and convert them into a 2D empirical model of electron density and magnetic field in radial distance and co-latitude, from which 2D maps of flow velocity, effective temperature and effective heat flux can be computed.

Background Patient adhesion to biosimilars DMARDs have become a big medico-economic issue. Indeed, savings will depend on penetration rate of biosimilars on the biologics market. Like generics, biosimilars are unknown by the general population and patients reluctance appears to be an obstacle to the diffusion of these therapeutics. Objectives To assess patients‘knowledge, information and concerns about biosimilars and to identify levers and obstacles to adhesion to biosimilars prescription. Methods National cross-sectional study assessing information, knowledge and concerns about biosimilars of french patients treated for a rheumatism (whether they were treated by a bDMARDs or not). The data were collected from march to july 2017 by an online assessment. Results 629 patients answered the assessment. 43% knew the definition of biosimilars. 65% felt unsufficiently informed about biosimilars. The principal sources of information were the rheumatologist and the patient associations. 44% of patients treated with a biosimilar were not informed before they received a biosimilar. Patients concerns focused on molecular structure (46%), efficacy (60%) and tolerance (57%) comparatively to originator bDMARDs. Receiving information about biosimilars and understanding the definition of biosimilarity were two characteristics associated with better adhesion to biosimilars. The rheumatologist was considered the most influent source of information about biosimilar. Patients trust him concerning the decision to switch from the originator biologic to its biosimilar. Patient were reluctant to substitution by the pharmacist (2%). Conclusions Biosimilars are largely unknown by french patients at present. Information seems to be instrumental in patient adhesion to biosimilars and in the preservation of the therapeutic relationship. References [1] Jacobs I, Singh E, Sewell L, Al-Sabbagh A, Shane LG. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence. MAI2016;937. [2] Beck M, Michel B, Rybarczyk-Vigouret M-C, Leveque D, Sordet C, Sibilia J, et al. Rheumatologists’ Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey. BioDrugs Clin Immunother Biopharm Gene Ther. Dec2016;30(6):585–92. Disclosure of Interest None declared

Texas Agricultural Extension Service (TAEX) has been experimenting with electronic information servers as an adjunct to traditional information distribution methods. Information servers may be easily established on inexpensive (< $1,500 US) computers running all free software. A brief analysis of present usage is presented, and cost savings documented. Some guidelines for on-line information providers are presented. Internet information servers allow access to a broader audience at lower cost than traditional distribution.

Expression of the rat growth hormone (rGH) gene is highly tissue-specific, being limited to a subset of cells in the anterior pituitary. DNA sequences within 237 bp of the transcription start site of the rGH gene play a major role in directing the expression of this gene in the pituitary. Transfection studies in cultured rat pituitary (GC) cells demonstrate that optimal expression of rGH requires the binding of at least two non-tissue-specific factors whose contribution to rGH expression is dependent on the binding of the pituitary-specific factor, Pit-1. Although the segment of DNA containing the elements to which these factors bind can direct pituitary-specific expression of a gene lacking upstream promoter elements, it cannot confer stimulation to either a heterologous or homologous promoter when placed downstream from the coding sequences. These results suggest that expression of the rGH gene exclusively in the pituitary is due to the activity of a tissue-specific promoter element, not an enh...